- $9.09bn
- $8.90bn
- $42.28m
Brief: Verona Pharma To Announce Top-Line Data From Phase 3 Enhance-1 Trial Of Nebulized Ensifentrine For COPD
Brief: Verona Pharma Says Nuance Pharma Receives Clearance To Begin Pivotal Clinical Trials With Ensifentrine For COPD In China
Brief: Verona Pharma PLC Announces Pricing Of Upsized Underwritten Public Offering
Brief: Verona Pharma PLC Announces Proposed Underwritten Public Offering
U.S. STOCKS ON THE MOVE-Applied DNA, Verona Pharma, SELLAS
Verona Pharma surges as lung disease therapy meets main goal in study
Brief: Verona Pharma To Announce Top-Line Data From Phase 3 Enhance-2 Trial Of Nebulized Ensifentrine For Copd
U.S. STOCKS ON THE MOVE-Hudson, Momenta Pharma, Inhibrx
U.S. STOCKS ON THE MOVE-Biomarin Pharma, Target, iRhythm Tech
U.S. STOCKS ON THE MOVE-Hudson, Sabre, Momenta Pharma
U.S. STOCKS ON THE MOVE-Verona Pharma, Lowe's Co, Kohl's Corp
Verona Pharma: Up on starting part 2 of pulmonary disease treatment trial
Verona Pharma: Doubles on raising $200 mln in private offering of stock
U.S. STOCKS ON THE MOVE-Akers Biosciences, Comstock, Virtusa
U.S. STOCKS ON THE MOVE-Akers Biosciences, Comstock, Futu Holdings
U.S. STOCKS ON THE MOVE-Comstock, Immunic, Verona Pharma
Verona Pharma: Rises on FDA go-ahead for late-stage lung disease drug study
NASDAQ RESUMED AT 08:38 AM
NASDAQ RESUMED AT 12:11 PM